Intraperitoneal Paclitaxel Shows Promise: Effective and Tolerable Combo for Gastric Cancer with Peritoneal Metastasis

In a phase II study, researchers explored the efficacy of intraperitoneal paclitaxel combined with S-1 and cisplatin for gastric cancer with peritoneal metastasis. Among 53 patients, the treatment achieved a 73.6% 1-year overall survival rate, meeting the primary endpoint. The median survival time was 19.4 months, and the 1-year progression-free survival rate reached 49.6%. While well-tolerated, with manageable toxicities, the study highlights the potential of this combination therapy for patients facing gastric cancer with peritoneal metastasis.